LR(9)

General Information


DRACP ID  DRACP01900

Peptide Name   LR(9)

Sequence  LRLRLRLRLRLRLRLRLR

Sequence Length  18

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma 96.7% Killing=500µg/ml MTS assay 24 h Patent

Hemolytic Activity  RBCs: 24%Hemolysis=250 µg/ml

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01900

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C108H209N45O19

Absent amino acids  ACDEFGHIKMNPQSTVWY

Common amino acids  LR

Mass  274554

Pl  13.4

Basic residues  9

Acidic residues  0

Hydrophobic residues  9

Net charge  9

Boman Index  -9000

Hydrophobicity  -35

Aliphatic Index  195

Half Life 
  Mammalian: 5.5 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US7091185B2

Patent Title  Periodic antimicrobial peptides

Other Iinformation  Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006

Other Published ID  US2005187151A1 




DBAASP ID  DBAASPS_13403

DRACP is developed by Dr.Zheng's team.